Screener
D&A at other companies
Other financials
Where this comes from
Reported directly by Amylyx Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:Depreciation.
The source filing: Amylyx Pharmaceuticals, Inc.’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 7:04 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-336682
| Line item | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Net loss | $(84,707) | $(77,350) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Stock-based compensation expense | 14,438 | 14,183 |
| Depreciation expense | 141 | 297 |
| Accretion of investment discounts, net | (1,826) | (3,226) |
| Charge for in-process research and development ("IPR&D") milestones | 4,000 | — |
| Other non-cash items | 84 | 264 |
| Changes in operating assets and liabilities: |
Item 1. Financial Statements.
FAQ
- What is Amylyx Pharmaceuticals, Inc.'s D&A?
- Amylyx Pharmaceuticals, Inc. (AMLX) reported D&A of $43K in Q2 2026.
- How has Amylyx Pharmaceuticals, Inc.'s D&A changed year-over-year?
- Amylyx Pharmaceuticals, Inc.'s D&A decreased by 69.5% year-over-year, from $141K to $43K.
- What is the long-term trend for Amylyx Pharmaceuticals, Inc.'s D&A?
- Over 4 years (2021 to 2025), Amylyx Pharmaceuticals, Inc.'s D&A has grown at a 78.3% compound annual growth rate (CAGR), from $52K to $525K.
- What does D&A mean?
- Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.
Ask your AI about Amylyx Pharmaceuticals, Inc.'s d&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude